Tenofovir/Emtricitabine Metabolites and Endogenous Nucleotide Exposures are associated with p16INK4a Expression in Subjects on Combination Therapy. Issue 5 (July 2016)
- Record Type:
- Journal Article
- Title:
- Tenofovir/Emtricitabine Metabolites and Endogenous Nucleotide Exposures are associated with p16INK4a Expression in Subjects on Combination Therapy. Issue 5 (July 2016)
- Main Title:
- Tenofovir/Emtricitabine Metabolites and Endogenous Nucleotide Exposures are associated with p16INK4a Expression in Subjects on Combination Therapy
- Authors:
- Dumond, Julie B
Francis, Owen
Cottrell, Mackenzie
Trezza, Christine
Prince, Heather MA
Mollan, Katie
Sykes, Craig
Torrice, Chad
White, Nicole
Malone, Stephanie
Wang, Ruili
Van Dam, Cornelius
Patterson, Kristine B
Hudgens, Michael G
Sharpless, Norman E
Forrest, Alan - Abstract:
- Background: HIV may amplify immunological, physiological and functional changes of ageing. We determined associations of frailty phenotype, a T-cell senescence marker (p16 INK4a expression), age and demographics with exposures of the intracellular metabolites (IM) and endogenous nucleotides (EN) of tenofovir/emtricitabine (TFV/FTC), efavirenz (EFV), atazanavir (ATV) and ritonavir (RTV). Methods: Plasma and peripheral blood mononuclear cell samples for drug, IM and EN concentrations were collected at four time points in HIV+ adults receiving TFV/FTC with EFV or ATV/RTV. Subjects underwent frailty phenotyping and p16 INK4a expression analysis. Non-compartmental analysis generated an area under the curve (AUC) for each analyte. Spearman rank correlation and Kruskal–Wallis tests were used to assess associations between AUC, demographics and ageing markers, adjusting for multiple comparisons with the Holm procedure. Results: Subjects ( n =79) ranged in age from 22–73 years (median 48 years); 48 were African-American, 24 were female, 54 received EFV. Three subjects (range 51–60 years) demonstrated frailty, with 17 subjects (range 26–60 years) demonstrating pre-frailty. Negative associations were observed between p16 INK4a expression and each of FTC-triphosphate (r=-0.45), deoxyadenosine triphosphate (dATP; r=-0.47) and deoxycytidine triphosphate (dCTP; r=-0.57) AUCs ( P -values ≤0.02). TFV and FTC AUCs were larger among subjects with lower renal function or higher chronologicalBackground: HIV may amplify immunological, physiological and functional changes of ageing. We determined associations of frailty phenotype, a T-cell senescence marker (p16 INK4a expression), age and demographics with exposures of the intracellular metabolites (IM) and endogenous nucleotides (EN) of tenofovir/emtricitabine (TFV/FTC), efavirenz (EFV), atazanavir (ATV) and ritonavir (RTV). Methods: Plasma and peripheral blood mononuclear cell samples for drug, IM and EN concentrations were collected at four time points in HIV+ adults receiving TFV/FTC with EFV or ATV/RTV. Subjects underwent frailty phenotyping and p16 INK4a expression analysis. Non-compartmental analysis generated an area under the curve (AUC) for each analyte. Spearman rank correlation and Kruskal–Wallis tests were used to assess associations between AUC, demographics and ageing markers, adjusting for multiple comparisons with the Holm procedure. Results: Subjects ( n =79) ranged in age from 22–73 years (median 48 years); 48 were African-American, 24 were female, 54 received EFV. Three subjects (range 51–60 years) demonstrated frailty, with 17 subjects (range 26–60 years) demonstrating pre-frailty. Negative associations were observed between p16 INK4a expression and each of FTC-triphosphate (r=-0.45), deoxyadenosine triphosphate (dATP; r=-0.47) and deoxycytidine triphosphate (dCTP; r=-0.57) AUCs ( P -values ≤0.02). TFV and FTC AUCs were larger among subjects with lower renal function or higher chronological age ( P -values ≤0.05). No associations were observed for EFV, ATV or RTV AUCs. Conclusions: Associations of IM/EN exposure and p16 INK4a expression observed here suggest that senescence may alter drug phosphorylation, metabolism or transport. This finding warrants further mechanistic study to ensure optimal treatment in the ageing HIV+ population. Clinicaltrials.gov NCT01180075. … (more)
- Is Part Of:
- Antiviral therapy. Volume 21:Issue 5(2016)
- Journal:
- Antiviral therapy
- Issue:
- Volume 21:Issue 5(2016)
- Issue Display:
- Volume 21, Issue 5 (2016)
- Year:
- 2016
- Volume:
- 21
- Issue:
- 5
- Issue Sort Value:
- 2016-0021-0005-0000
- Page Start:
- 441
- Page End:
- 445
- Publication Date:
- 2016-07
- Subjects:
- Antiviral agents -- Periodicals
Antiviral Agents -- therapeutic use
Virus Diseases -- therapy
Viruses -- drug effects
Antiviral agents
Periodical
Electronic journals
Periodicals
616.9106 - Journal URLs:
- http://www.intmedpress.com/General/showSectionSub.cfm?SectionID=2&SectionSubID=1&SectionSubSubID=1 ↗
http://www.uk.sagepub.com/home.nav ↗ - DOI:
- 10.3851/IMP3017 ↗
- Languages:
- English
- ISSNs:
- 1359-6535
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 17213.xml